NLNK vs. EBS, RGLS, BOLT, FBIO, RIGL, MACK, VSTM, VNDA, XOMA, and LXRX
Should you be buying NewLink Genetics stock or one of its competitors? The main competitors of NewLink Genetics include Emergent BioSolutions (EBS), Regulus Therapeutics (RGLS), Bolt Biotherapeutics (BOLT), Fortress Biotech (FBIO), Rigel Pharmaceuticals (RIGL), Merrimack Pharmaceuticals (MACK), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "biotechnology" industry.
Emergent BioSolutions (NYSE:EBS) and NewLink Genetics (NASDAQ:NLNK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.
Emergent BioSolutions received 27 more outperform votes than NewLink Genetics when rated by MarketBeat users. However, 71.56% of users gave NewLink Genetics an outperform vote while only 66.45% of users gave Emergent BioSolutions an outperform vote.
78.4% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 32.3% of NewLink Genetics shares are held by institutional investors. 1.2% of Emergent BioSolutions shares are held by insiders. Comparatively, 12.7% of NewLink Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Emergent BioSolutions presently has a consensus target price of $5.00, indicating a potential upside of 28.53%. Given NewLink Genetics' higher probable upside, equities analysts plainly believe Emergent BioSolutions is more favorable than NewLink Genetics.
Emergent BioSolutions has a net margin of -47.68% compared to Emergent BioSolutions' net margin of -4,592.84%. NewLink Genetics' return on equity of -18.53% beat Emergent BioSolutions' return on equity.
In the previous week, Emergent BioSolutions had 25 more articles in the media than NewLink Genetics. MarketBeat recorded 25 mentions for Emergent BioSolutions and 0 mentions for NewLink Genetics. NewLink Genetics' average media sentiment score of 0.35 beat Emergent BioSolutions' score of 0.00 indicating that Emergent BioSolutions is being referred to more favorably in the media.
Emergent BioSolutions has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, NewLink Genetics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.
NewLink Genetics has lower revenue, but higher earnings than Emergent BioSolutions. NewLink Genetics is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.
Summary
Emergent BioSolutions beats NewLink Genetics on 12 of the 17 factors compared between the two stocks.
Get NewLink Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NLNK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NLNK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NewLink Genetics Competitors List
Related Companies and Tools
